Current therapies in primary immune thrombocytopenia

Seminars in Thrombosis and Hemostasis

Volumn 37, Issue 6, 2011, Pages 621-630

  Pels, Salley G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

corticosteroids; Immune thrombocytopenia; immunoglobulin; rituximab; thrombopoietin

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; ELTROMBOPAG; HEMATOLOGIC AGENT; IMMUNOGLOBULIN; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RHESUS D ANTIBODY; RITUXIMAB; ROMIPLOSTIM; STEROID; THROMBOPOIETIN RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ARTHRALGIA; B LYMPHOCYTE; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG ERUPTION; DRUG FEVER; DRUG MEGADOSE; FATIGUE; HEADACHE; HUMAN; IMMUNE THROMBOCYTOPENIA; IMMUNOPATHOLOGY; LYMPHADENOPATHY; MYELOFIBROSIS; NAUSEA; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SPLENECTOMY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; URTICARIA;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD PLATELETS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, THROMBOPOIETIN; SPLENECTOMY;

EID: 81755184028     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0031-1291372     Document Type: Review

References (80)

1. Rodeghiero F, Stasi R, Gernsheimer T et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009 113 11 2386-2393
2. Beardsley D S. Pathophysiology of immune thrombocytopenic purpura. Blood Rev 2002 16 1 13-14 (Pubitemid 34293545)
3. Cines D B., Liebman H A. The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation. Hematol Oncol Clin North Am 2009 23 6 1155-1161
4. Evans R S., Takahashi K, Duane R T., Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med 1951 87 1 48-65
5. Panitsas F P., Theodoropoulou M, Kouraklis A et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004 103 7 2645-2647 (Pubitemid 38393019)
6. Stasi R, Cooper N, Del Poeta G et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008 112 4 1147-1150
7. + regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome. Eur J Haematol 2007 79 4 310-316 (Pubitemid 47390130)
8. McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004 103 4 1364-1369 (Pubitemid 38168649)
9. Provan D, Stasi R, Newland A C. et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010 115 2 168-186
10. Dickerhoff R, von Ruecker A. The clinical course of immune thrombocytopenic purpura in children who did not receive intravenous immunoglobulins or sustained prednisone treatment. J Pediatr 2000 137 5 629-632
11. George J N., Woolf S H., Raskob G E. et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996 88 1 3-40 (Pubitemid 26230668)
12. Kühne T, Buchanan G R., Zimmerman S et al, Intercontinental Childhood ITP Study Group Intercontinental Childhood ITP Study Group. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 2003 143 5 605-608 (Pubitemid 37452786)
13. George J N. Initial management of immune thrombocytopenic purpura in children: is supportive counseling without therapeutic intervention sufficient? J Pediatr 2000 137 5 598-600
14. Tarantino M D., Buchanan G R. The pros and cons of drug therapy for immune thrombocytopenic purpura in children. Hematol Oncol Clin North Am 2004 18 6 1301-1314 viii (Pubitemid 39423416)
15. De Mattia D, Del Principe D, Del Vecchio G C. et al. Acute childhood idiopathic thrombocytopenic purpura: AIEOP consensus guidelines for diagnosis and treatment. Associazione Italiana di Ematologia e Oncologia Pediatrica. Haematologica 2000 85 4 420-424 (Pubitemid 30318517)
16. Buchanan G R., de Alarcon P A., Feig S A. et al. Acute idiopathic thrombocytopenic purpuramanagement in childhood. Blood 1997 89 4 1464-1465 author reply 1466 (Pubitemid 27080014)
17. Bolton-Maggs P H. Acute idiopathic thrombocytopenic purpuramanagement in childhood. Blood 1997 89 4 1465 author reply 1466
18. Sutor A H., Dickeroff R, Gaedicke G et al. Hamostasiologie: acute postinffektiose immunothrombozytopenie im kindersalter. [Acute postinfectious immune thrombocytopenia in children.] In: Leitlinien kenderheilkunde und jugendmedizin. [Guidelines for pediatric and youth medicine.]. Munich, Germany Urban & Fischer 1999 23-27
19. Provan D, Newland A, Norfolk D et al, British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003 120 4 574-596
20. Cohen Y C., Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Intern Med 2000 160 11 1630-1638 (Pubitemid 30367902)
21. Imbach P, Barandun S, d'Apuzzo V et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981 1 8232 1228-1231
22. Crow A R., Lazarus A H. The mechanisms of action of intravenous immunoglobulin and polyclonal anti-d immunoglobulin in the amelioration of immune thrombocytopenic purpura: what do we really know? Transfus Med Rev 2008 22 2 103-116 (Pubitemid 351381948)
23. Blanchette V S., Luke B, Andrew M et al. A prospective, randomized trial of high-dose intravenous immune globulin G therapy, oral prednisone therapy, and no therapy in childhood acute immune thrombocytopenic purpura. J Pediatr 1993 123 6 989-995 (Pubitemid 23353267)
24. Blanchette V, Imbach P, Andrew M et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994 344 8924 703-707 (Pubitemid 24281420)
25. Beck C E., Nathan P C., Parkin P C., Blanchette V S., Macarthur C. Corticosteroids versus intravenous immune globulin for the treatment of acute immune thrombocytopenic purpura in children: a systematic review and meta-analysis of randomized controlled trials. J Pediatr 2005 147 4 521-527 (Pubitemid 41446548)
26. Blanchette V, Bolton-Maggs P. Childhood immune thrombocytopenic purpura: diagnosis and management. Hematol Oncol Clin North Am 2010 24 1 249-273
27. Godeau B, Chevret S, Varet B et al, French ATIP Study Group. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002 359 9300 23-29 (Pubitemid 34119192)
28. Balaraman R. Treatment of severe autoimmune thrombocytopenic purpura. Lancet 2002 359 9325 2279-2280 author reply 2279-2280 (Pubitemid 34717994)
29. Carradice D. Treatment of severe autoimmune thrombocytopenic purpura. Lancet 2002 359 9325 2279 author reply 2279-2280
30. Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 1993 78 6, Suppl 2 35-40
31. Cayco A V., Perazella M A., Hayslett J P. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997 8 11 1788-1794
32. Sartorius J A. Steroid treatment of idiopathic thrombocytopenic purpura in children. Preliminary results of a randomized cooperative study. Am J Pediatr Hematol Oncol 1984 6 2 165-169 (Pubitemid 14029400)
33. Carcao M D., Zipursky A, Butchart S, Leaker M, Blanchette V S. Short-course oral prednisone therapy in children presenting with acute immune thrombocytopenic purpura (ITP). Acta Paediatr Suppl 1998 424 71-74 (Pubitemid 28410866)
34. Ozsoylu S, Irken G, Karabent A. High-dose intravenous methylprednisolone for acute childhood idiopathic thrombocytopenic purpura. Eur J Haematol 1989 42 5 431-435 (Pubitemid 19150277)
35. Ancona K G., Parker R I., Atlas M P., Prakash D. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol 2002 24 7 540-544 (Pubitemid 36004540)
36. Naithani R, Mahapatra M, Kumar R, Mishra P, Saxena R. High dose dexamethasone therapy shows better responses in acute immune thrombocytopenia than in chronic immune thrombocytopenia. Platelets 2010 21 4 270-273
37. Cheng Y, Wong R S., Soo Y O. et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003 349 9 831-836 (Pubitemid 37025402)
38. Borst F, Keuning J J., van Hulsteijn H, Sinnige H, Vreugdenhil G. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults. Ann Hematol 2004 83 12 764-768 (Pubitemid 39485547)
39. Mazzucconi M G., Fazi P, Bernasconi S et al, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Thrombocytopenia Working Party. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007 109 4 1401-1407 (Pubitemid 46239570)
40. Alpdogan O, Budak-Alpdogan T, Ratip S et al. Efficacy of high-dose methylprednisolone as a first-line therapy in adult patients with idiopathic thrombocytopenic purpura. Br J Haematol 1998 103 4 1061-1063 (Pubitemid 29012643)
41. Kuku I, Aydogdu I, Kaya E et al. The early and long-term results of oral high-dose methylprednisolone treatment in adult patients with idiopathic thrombocytopenic purpura. Eur J Haematol 2005 74 3 271-272
42. Cheung E, Liebman H A. Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics 2009 3 57-62
43. Scaradavou A, Woo B, Woloski B M. et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997 89 8 2689-2700 (Pubitemid 27172553)
44. Tarantino M D., Madden R M., Fennewald D L., Patel C C., Bertolone S J. Treatment of childhood acute immune thrombocytopenic purpura with anti-D immune globulin or pooled immune globulin. J Pediatr 1999 134 1 21-26 (Pubitemid 29048674)
45. Tarantino M D., Young G, Bertolone S J. et al, Acute ITP Study Group. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children. J Pediatr 2006 148 4 489-494
46. Kane I, Ragucci D, Shatat I F., Bussel J, Kalpatthi R. Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura. Br J Haematol 2010 149 1 79-83
47. Shahgholi E, Vosough P, Sotoudeh K et al. Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura. Indian J Pediatr 2008 75 12 1231-1235
48. Newman G C., Novoa M V., Fodero E M., Lesser M L., Woloski B M., Bussel J B. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001 112 4 1076-1078 (Pubitemid 32322940)
49. Gaines A R., Lee-Stroka H, Byrne K et al. Investigation of whether the acute hemolysis associated with Rh(o)(D) immune globulin intravenous (human) administration for treatment of immune thrombocytopenic purpura is consistent with the acute hemolytic transfusion reaction model. Transfusion 2009 49 6 1050-1058
50. Gaines A R. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005 106 5 1532-1537 (Pubitemid 41208562)
51. Saleh M N., Gutheil J, Moore M et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol 2000 27 6, Suppl 12 99-103 (Pubitemid 32164602)
52. Stasi R, Stipa E, Forte V, Meo P, Amadori S. Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. Blood 2002 99 10 3872-3873 (Pubitemid 34534570)
53. Wang J, Wiley J M., Luddy R, Greenberg J, Feuerstein M A., Bussel J B. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr 2005 146 2 217-221 (Pubitemid 40202812)
54. Bennett C M., Rogers Z R., Kinnamon D D. et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006 107 7 2639-2642
55. Cooper N, Stasi R, Cunningham-Rundles S et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004 125 2 232-239 (Pubitemid 38534976)
56. Arnold D M., Dentali F, Crowther M A. et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007 146 1 25-33 (Pubitemid 351650318)
57. Godeau B, Porcher R, Fain O et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study. Blood 2008 112 4 999-1004
58. Fianchi L, Rossi E, Murri R, De Stefano V, Pagano L, Leone G. Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. Ann Hematol 2007 86 3 225-226 (Pubitemid 46195997)
59. Carson K R., Evens A M., Richey E A. et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009 113 20 4834-4840
60. Hitzrot J M. Splenectomy in Hemorrhagic Purpura: Idiopathic Purpura, Essential Thrombopenie (Frank). Purpura Hemorrhagic Protopathique (Hayem). Ann Surg 1923 78 2 185-190
61. Kühne T, Blanchette V, Buchanan G R. et al, Intercontinental Childhood ITP Study Group. Splenectomy in children with idiopathic thrombocytopenic purpura: A prospective study of 134 children from the Intercontinental Childhood ITP Study Group. Pediatr Blood Cancer 2007 49 6 829-834 (Pubitemid 47519522)
62. Mantadakis E, Buchanan G R. Elective splenectomy in children with idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2000 22 2 148-153 (Pubitemid 32290151)
63. El-Alfy M S., El-Tawil M M., Shahein N. 5- to 16-year follow-up following splenectomy in chronic immune thrombocytopenic purpura in children. Acta Haematol 2003 110 1 20-24 (Pubitemid 37140399)
64. Aronis S, Platokouki H, Avgeri M, Pergantou H, Keramidas D. Retrospective evaluation of long-term efficacy and safety of splenectomy in chronic idiopathic thrombocytopenic purpura in children. Acta Paediatr 2004 93 5 638-642 (Pubitemid 38570231)
65. Bolton-Maggs P H., Dickerhoff R, Vora A J. The nontreatment of childhood ITP (or the art of medicine consists of amusing the patient until nature cures the disease). Semin Thromb Hemost 2001 27 3 269-275 (Pubitemid 32550168)
66. Schwartz J, Leber M D., Gillis S, Giunta A, Eldor A, Bussel J B. Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 2003 72 2 94-98 (Pubitemid 36164342)
67. Han J J., Baek S K., Lee J J., Kim S Y., Cho K S., Yoon H J. Long-term outcomes of a 5-year follow up of patients with immune thrombocytopenic purpura after splenectomy. Korean J Hepatol 2010 45 3 197-204
68. Kojouri K, Vesely S K., Terrell D R., George J N. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004 104 9 2623-2634 (Pubitemid 39434940)
69. Stasi R, Newland A, Thornton P, Pabinger I. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Ann Hematol 2010 89 12 1185-1195
70. Bisharat N, Omari H, Lavi I, Raz R. Risk of infection and death among post-splenectomy patients. J Infect 2001 43 3 182-186 (Pubitemid 34211099)
71. Kaushansky K, Lok S, Holly R D. et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994 369 6481 568-571 (Pubitemid 24192526)
72. Kuter D J. New thrombopoietic growth factors. Blood 2007 109 11 4607-4616 (Pubitemid 46827750)
73. Buchanan G R., Bomgaars L, Bussel J B. et al. A Randomized, Double-Blind, Placebo-Controlled Phase 1/2 Study to Determine the Safety and Efficacy of Romiplostim in Children with Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP). Blood (ASH Annual Meeting Abstracts) 2009 114 680
74. Elalfy M S., Abdelmaksoud A A., Eltonbary K Y. Romiplostim (N-Plate) In Children with Chronic Refractory ITP. Blood (ASH Annual Meeting Abstracts) 2010 116 1443
75. Kuter D J., Bussel J B., Lyons R M. et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 2008 371 9610 395-403 (Pubitemid 351181334)
76. Bussel J B., Kuter D J., Pullarkat V, Lyons R M., Guo M, Nichol J L. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 2009 113 10 2161-2171
77. Kuter D J., Bussel J B., Newland A et al. Long-Term Efficacy and Safety of Romiplostim Treatment of Adult Patients with Chronic Immune Thrombocytopenia (ITP): Final Report from an Open-Label Extension Study. Blood (ASH Annual Meeting Abstracts) 2010 116 68
78. Bussel J B., Provan D, Shamsi T et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009 373 9664 641-648
79. Cheng G, Saleh M N., Marcher C et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011 377 9763 393-402
80. Neunert C, Lim W, Crowther M et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011 117 16 4190-4207